CGM in Type 2 Diabetes: Can It Reduce Mortality?

What did the study find about CGM and mortality?

Research reported at the European Association for the Study of Diabetes meeting compared 13,935 people starting CGM with an equally sized matched group of nonusers. At one year, deaths occurred in 1.16% of CGM users versus 2.09% of nonusers. [EASD study report](https://www.eurekalert.org/news-releases/1145295).

The researchers used existing health records to approximate a clinical trial, without randomly assigning treatment. Differences in care engagement or other unmeasured factors could influence outcomes. Medication changes during follow-up were not examined. Researchers from device manufacturer Abbott participated, and the lead investigator disclosed industry relationships. These findings warrant confirmation in prospective research. [EASD methods and disclosures](https://www.eurekalert.org/news-releases/1145295).

How can continuous glucose monitoring improve diabetes care?

A finger-stick test captures glucose at a particular moment. A CGM sensor estimates glucose in the fluid between cells repeatedly, making changes easier to follow. Many devices provide alerts when readings cross selected thresholds. This information can reveal patterns around meals, activity and sleep that occasional checks may miss. The potential benefit comes from using those patterns to guide care, with appropriate education and follow-up. [NIDDK explanation of CGM](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/continuous-glucose-monitoring).

Stronger evidence for improved glucose control comes from the MOBILE randomized trial, published in JAMA in 2021. It enrolled 175 adults with inadequately controlled type 2 diabetes using basal insulin without mealtime insulin. Over eight months, HbA1c fell by 1.1 percentage points in the CGM group and 0.6 percentage points in the blood glucose meter group. HbA1c reflects average glucose over preceding months. The trial demonstrated better glucose management; its findings do not establish that CGM prevents heart attacks or extends life. [MOBILE randomized trial](https://jamanetwork.com/journals/jama/fullarticle/2780593).

Who should consider CGM when taking basal insulin?

Basal insulin provides background insulin coverage, including between meals and overnight. The American Diabetes Association's Standards of Care recommend CGM for adults receiving insulin, with device selection tailored to individual circumstances and preferences. Recurrent low readings, substantial glucose variability or difficulty reaching an agreed glucose goal are useful issues to raise during a review. Monitoring data can also help clinicians recognize when simply increasing basal insulin may be inappropriate. [ADA treatment guidance](https://doi.org/10.2337/dc26-s009).

Successful use requires a practical plan: understand alerts, know when to check a reading with a blood glucose meter and arrange review of recurring patterns. Sensor costs, replacement supplies and skin irritation can affect continued use. Patients should agree with their care team how readings will guide treatment rather than assuming every fluctuation requires an insulin adjustment. The device supplies information; education and access to care help make that information useful. [NIDDK guidance on benefits and limitations](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/continuous-glucose-monitoring).